Isaac Ssewanyana
ID: UNCST-2020-R014336
|
ConfiSign HIV/Syphilis Combo Self-Test: Evaluation of Clinical Performance and Usability in the hands of untrained users.
REFNo: HS6687ES
Untrained users will either take part in the label comprehension study and results interpretation study (part A) or in the observed untrained user study (part B). Untrained users enrolled for the label comprehension and results interpretation study (part A), shall not participate in the observed user study (part B) and vice versa.,The primary and overall objective of this study is to evaluate the performance and the usability of the ConfiSign HIV/Syphilis Combo Self-Test in the hands of untrained users from a low prevalence HIV region (< 5%) who have no, or limited experience in self-testing. ,
|
Uganda |
2025-10-29 16:22:26 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Specioza Namakula
ID: UNCST-2025-R021710
|
EMPOWERING MOBILITY: Assessing the Impact of Buffalo Bicycles on Refugee and host Communities in Uganda. A case study of Bidi Bidi, Rhino Camp and Palabek refugee settlements
REFNo: SS4566ES
I. To generate data that will support Learning and evidence-based decision making.
II. To provide systematic and objective information for bicycle usage in refugee communities.
III. Generating information that is required to inform advocacy and further bicycle provision for vulnerable communities.
IV. To determine the effectiveness, efficiency and relevance of bicycles in improving accessibility to essential services like education, health and economic empowerment.
|
Uganda |
2025-10-29 16:20:00 |
2028-10-29 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Victor Musiime
ID: UNCST-2021-R013794
|
Enhancing Novel Research for Inflammation and Cognitive Health among Adolescents and Young Adults Living with Perinatally Acquired HIV and Adversity (ENRICH+)
REFNo: HS6607ES
Specific Aim 1: Investigate differences in ID and NCI in demographically matched, virally suppressed PHIV and HHIV, as well as HUU AYA (15-25 years old) in Uganda while controlling for chronic adversities. Hypothesis 1 (H1): Both ID and NCI will be respectively higher in PHIV vs. HHIV vs. HUU AYA. H2: Within the two HIV groups, those with delayed ART initiation and lower nadir CD4 cell count at ART initiation will have higher ID and worse NCI.
Specific Aim 2: Investigate the relationship between ID and NCI in AYA within all three groups (PHIV, HHIV and HUU) controlling for chronic adversities. H3: There will be a positive association between ID and NCI in each group. H4: In a subset of PHIV and HUU AYA with prior repeated measures of ID, worsening trajectories of ID in PHIV across 6 years will be associated with worse NCI.
Specific Aim 3: Investigate the effects of co-occurring adversities (i.e., profiles) on the relationships between HIV, ID, and NCI. H5: Adversity profiles will be more severe respectively in PHIV vs. HHIV vs. HUU. H6: The strength of association between medical and psychosocial (e.g., stigma, mental health) adversities, ID and NCI will be strongest in PHIV vs. HHIV vs. HUU, respectively.
|
Uganda |
2025-10-29 16:07:10 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Henry Mugerwa
ID: UNCST-2019-R000420
|
A5402 An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons with HIV
REFNo: HS6604ES
1.2 Primary Objectives
1.2.1 To compare pramipexole to escitalopram in the treatment of MDD (and comorbid MDD with MND) based on the Beck Depression Inventory-II (BDI-II/BDI-2) total score [Beck 1996] from baseline to week 24.
1.2.2 To evaluate the safety of pramipexole and escitalopram in PWH having MDD (and comorbid MDD with MND) from baseline to week 24.
1.3 Secondary Objectives
1.3.1 To compare pramipexole to escitalopram in the treatment of MDD using MDD caseness, neurocognitive outcomes, and functional status from baseline to week 24.
1.3.2 To compare the depression, neurocognitive, and functional status outcomes in PWH with MDD alone and with comorbid MDD with MND treated with pramipexole versus escitalopram from baseline to week 24.
1.3.3 To compare the impact of pramipexole and escitalopram on all outcomes above by female versus male sex (assigned at birth) from baseline to week 24.
1.3.4 To determine the impact of pramipexole compared to escitalopram on the measure of HIV-1 RNA viral load in the peripheral blood.
1.4 Exploratory Objectives
1.4.1 To characterize associations between escitalopram trough concentrations and treatment efficacy (BDI-II/BDI-2 total score) as well as participant adverse events (adverse event frequency, severity, and discontinuation rates).
1.4.2 To characterize associations between escitalopram trough concentrations and genetic polymorphisms that affect metabolizing enzymes of escitalopram (known metabolizing enzymes include CYP2C19, CYP2D6, and CYP3A4).
1.4.3 To explore associations between cerebrospinal fluid (CSF) concentrations of escitalopram and BDI-II/BDI-2 total score.
1.4.4 To evaluate adverse events potentially related to drug interactions between antiretroviral therapy (ART) and escitalopram and pramipexole, respectively.
1.5 Substudy Objective
1.5.1 CSF Substudy
To compare the impact of pramipexole and escitalopram on biomarker outcomes in a CSF substudy of participants with MDD alone.
|
Uganda |
2025-10-29 16:04:25 |
2028-10-29 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Abel Kakuru
ID: UNCST-2022-R009193
|
Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the prevention of febrile illnesses in children with sickle cell anemia: a double-blind randomized controlled trial
REFNo: HS6294ES
1.
To compare the incidence of all-cause febrile illness among children with sickle cell anemia randomized to receive monthly SP vs. monthly DP+SP.
2.
To compare the incidence of adverse events among children with sickle cell anemia randomised to receive monthly SP vs. monthly DP+SP.
3.
To compare the prevalence of markers of antimalarial resistance, including those associated with SP and DP resistance, among parasitemic children with sickle cell anemia randomized to receive monthly SP vs. monthly DP+SP.
|
Uganda |
2025-10-29 15:55:44 |
2028-10-29 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jane Kabami
ID: UNCST-2021-R012588
|
Peerled Dynamic Choice HIV Prevention for Women. The Peer-led DCP Study
REFNo: HS6556ES
To refine and pilot test a Peer-led Dynamic Choice HIV Prevention intervention for women at elevated HIV risk in southwestern Uganda
|
Uganda |
2025-10-29 12:53:43 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Hannah Tusabe Not Applicable
ID: UNCST-2025-R022045
|
EXPLORING THE IMPLEMENTATION OF EARLY GRADE READING METHODOLOGY IN UGANDA PRIMARY SCHOOLS
REFNo: SS4540ES
1.3.1 Main Objective
To explore the implementation of Early-Grade Reading Methodology in primary schools in Uganda.
1.3.2 Specific Objectives
To establish the current practices of Early-Grade Reading methodologies by teachers in primary schools in Uganda.
To identify the challenges teachers face in implementing Early-Grade Reading methodologies in their classrooms.
To determine strategies that can be adopted to improve the implementation of Early-Grade Reading methodologies in Ugandan primary schools.
|
Uganda |
2025-10-29 12:51:10 |
2028-10-29 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
richard kasirye
ID: UNCST-2025-R018157
|
Instructional Technologies for Teacher Education at Busitema University: Application of Skills to Practice
REFNo: SS4450ES
The study aims to answer: How do Busitema University’s teacher education alumni apply ICT knowledge and skills in the secondary schools where they teach? What are their experiences in using ICT in their classrooms? How can the university improve the teacher education program to better prepare graduates for technology-enhanced teaching?
|
Uganda |
2025-10-29 12:48:06 |
2028-10-29 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
.jpg)
|
ALEX KAYONGO
ID: UNCST-2019-R001641
|
Clonotyping Airway T-cells to Uncover Microbiome-Specific Inflammotypes in HIV-Associated COPD
REFNo: HS6625ES
Study Aim:
To investigate the airway microbiome-specific inflammotypes in COPD among HIV-infected individuals in a rural Uganda.
Specific objectives
1.To determine, in vitro, the CD4+T-cell clonotypic library specific to airway bacterial species associated with COPD among HIV-infected individuals in rural Uganda.
2.To determine, ex vivo, the microbiome-specific clonotypic landscape of BAL-derived CD4+T cells from a cohort of individuals stratified by HIV and COPD in rural Uganda.
3.To validate airway microbiome-specific inflammotypes among individuals with COPD transitioning from stable disease to exacerbation and back to stable disease.
|
Uganda |
2025-10-29 12:47:04 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
AGNESS NATABA
ID: UNCST-2024-R002018
|
Reclaiming Rights:Bunyoro Kitara Kingdom Women and their Quest for Reparative Justice from British Colonialism
REFNo: SS4501ES
1. To examine how historical injustices faced by women in the Bunyoro Kitara Kingdom during British colonial rule affected their cultural setting.
2. To evaluate existing reparative justice efforts for women in the Bunyoro Kitara Kingdom.
3. To assess how gender-responsiveness the existing reparative efforts are in fostering inclusive justice, healing, and environmental justice for women in the Bunyoro Kitara Kingdom.
|
Uganda |
2025-10-29 12:44:59 |
2028-10-29 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|